Literature DB >> 9433475

Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA).

G Wang1, E Csernok, K de Groot, W L Gross.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) are used as diagnostic markers for systemic vasculitis. However, the specificity and sensitivity of ANCA detection differs from centre to centre due in large part to variations in methodology. We compared 8 commercial ELISA kits and an in-house method (HM) for their specificity and sensitivity in detecting ANCA against proteinase 3 (PR3-ANCA, 7 kits) and meyloperoxidse (MPO-ANCA, 8 kits). Sera from 5 patients with systemic lupus erythematosus (SLE), 28 with Wegener's granulomatosis (WG), 22 with microscopic polyangiitis (MPA), 5 with idiopathic rapidly progressive glomerulonephritis (RPGN), and 5 healthy controls were examined by both the indirect immunofluorescence technique (IFT) and the ELISA kits. Sera from healthy controls and patients with SLE or cANCA-negative WG were shown to be PR3-ANCA negative by all 7 PR3-ANCA kits. In 25 cANCA-positive sera from WG patients, PR3-ANCA positivity ranged from 44% to 84%. An absolute concordance among the 7 kits was noted in 56% of the cANCA-positive samples. The PR3-ANCA levels in 5 of the 7 kits correlated with the cANCA titers in IFT. Sera from the healthy controls and 4 out of the 5 SLE and pANCA-negative patients were found to be MPO-ANCA negative in all 8 MPO-ANCA kits. In 20 pANCA-positive sera, MPO-ANCA positivity ranged from 25% to 75%. Thirty-five percent of MPO-ANCA-positive sera were confirmed by capture ELISA, immunoblot and inhibition assay. The concordance rate was only 30% among pANCA-positive sera in the 8 MPO-ANCA kits. No significant correlation was observed between pANCA titers and MPO-ANCA levels. The HM showed that 65% of cANCA-positive sera were PR3-ANCA positive, and 45% of pANCA-positive sera were MPO-ANCA positive. Our results indicate that the sensitivities and specificities for ANCA detection differ significantly among the commercial kits tested and underline the necessity of establishing uniform international standards for ANCA ELISA procedures in order to permit more reliable interpretation and comparison of data.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9433475     DOI: 10.1016/s0022-1759(97)00154-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

3.  Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?

Authors:  J U Holle; B Hellmich; M Backes; W L Gross; E Csernok
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

4.  Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies.

Authors:  Qian Sun; Boris Calderon; Zhen Zhao
Journal:  Clin Chim Acta       Date:  2017-05-08       Impact factor: 3.786

Review 5.  Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody.

Authors:  K Suzuki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

6.  Indirect immunofluorescence (IIF) of normal washed peripheral blood cells to demonstrate antineutrophil cytoplasmic antibodies (ANCA).

Authors:  B Paspaliaris; M Pamio; J Savige
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

7.  Rapid decrease of anti-beta-glucan antibody as an indicator for early diagnosis of carinii pneumonitis and deep mycotic infections following immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Masaharu Yoshida; Ken-ichi Ishibashi; Shunsuke Hida; Noriko Yoshikawa; Iwao Nakabayashi; Masakazu Akashi; Taeko Watanabe; Tomohiro Tomiyasu; Naohito Ohno
Journal:  Clin Rheumatol       Date:  2009-02-04       Impact factor: 2.980

Review 8.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.